Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al.

Szczegóły
Comments

Tytuł:: Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al.
Autorzy:: Yokogawa N; Tokyo Metropolitan Tama Medical Center.
Ohno-Tanaka A; Tokyo Metropolitan Tama Medical Center.
Hashiguchi M; Keio University, Tokyo, Japan.
Shimizu M; Shujitsu University School of Pharmacy, Okayama, Japan.
Ozawa H; Kawasaki Municipal Hospital, Kanagawa, Japan.
Ueno S; Nagoya University, Nagoya, Japan.
Shinoda K; Saitama Medical University, Saitama, Japan.
Browning DJ; Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, NC.
Źródło:: Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2021 Feb; Vol. 73 (2), pp. 358-359. Date of Electronic Publication: 2021 Jan 01.
Typ publikacji:: Letter; Comment
Język:: English
Imprint Name(s):: Original Publication: Malden, MA : Wiley, [2014]-
MeSH Terms:: Antirheumatic Agents*/adverse effects
Drug-Related Side Effects and Adverse Reactions*
Retinal Diseases*/chemically induced
Humans ; Hydroxychloroquine/adverse effects
References:: Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol 2020;72:448-53.
Lenfant T, Salah S, Leroux G, Bousquet E, Le Guern V, Chasset F, et al. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology (Oxford) 2020. E-pub ahead of print.
Yokogawa N, Eto H, Tanikawa A, Ikeda T, Yamamoto K, Takahashi T, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol 2017;69:791-9.
Morita S, Takahashi T, Yoshida Y, Yokota N. Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus. Ther Drug Monit 2016;38:259-67.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 2016;123:1386-94.
Browning DJ, Yokogawa N, Greenberg PB, Perlman E. Rethinking the hydroxychloroquine dosing and retinopathy screening guidelines. Am J Ophthalmol 2020;219:101-6.
Substance Nomenclature:: 0 (Antirheumatic Agents)
4QWG6N8QKH (Hydroxychloroquine)
Entry Date(s):: Date Created: 20200829 Date Completed: 20210224 Latest Revision: 20210224
Update Code:: 20240105
DOI:: 10.1002/art.41497
PMID:: 32856370
: Opinia redakcyjna

Full Text Finder

Comment on: Arthritis Rheumatol. 2020 Mar;72(3):448-453. (PMID: 31532077)
Comment in: Arthritis Rheumatol. 2021 Feb;73(2):359. (PMID: 32936524)

Informacja